Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Cancer Pain Killer Metastron Recommended for Approval
May 14, 2007
- Eplerenone, Topiramate, Rocuronium Recommended for Approval
May 14, 2007
- BUSINESS NEWS IN BRIEF
April 30, 2007
- OINION：Times Are a Changin'
April 30, 2007
- NEW PRODUCTS
April 30, 2007
- Diabetes Care Should Be Standardized: Critical Path Seminar
April 30, 2007
- Zydus Acquires Nippon Universal
April 30, 2007
- Cancer Deaths Should Decrease by Half in Next 10 Years: Dr Kakizoe
April 30, 2007
- Generics to Be NHI Price-Listed Twice a Year from FY2007
April 30, 2007
- Korosho Study Group Issues GL on Terminal Care
April 30, 2007
- Generic Substitution Rate Remains "very Low" Despite New Prescription Form: Chuikyo
April 30, 2007
- Doctors' Average Monthly Salaries Up to \761,000
April 30, 2007
- Information on Incidence of ADRs Is Not Intellectual Property: PMDA's Mr Kishida
April 30, 2007
- Status of 5 Major Diseases in 2015 Surveyed: JHSF
April 30, 2007
- 29 New Drugs Approved
April 30, 2007
- Plavix to Drive Sales of sanofi-aventis in 2007: Mr Fauchet
April 30, 2007
- Expert Group Starts Discussing Compassionate Use of Unapproved Drugs
April 30, 2007
- JPMA Seminar on Innovation
April 30, 2007
- JPMA to Propose New Drug Pricing System in May
April 30, 2007
- Joint Consultation Services by PMDA, FDA, EMEA Suggested by Mr Nakagaki of Korosho
April 30, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…